US2023279102A1PendingUtilityA1

Anti-tigit antibodies and methods of use

84
Assignee: GENENTECH INCPriority: Sep 25, 2015Filed: Dec 7, 2022Published: Sep 7, 2023
Est. expirySep 25, 2035(~9.1 yrs left)· nominal 20-yr term from priority
Inventors:Jane L. GroganRobert J. JohnstonYan WuWei-Ching LiangPatrick J. LupardusMahesh YadavDhaya SeshasayeeMeredith Hazen
C07K 16/28A61K 38/177A61K 39/39558A61K 45/06C07K 16/2818C07K 16/2827C07K 16/2878C07K 16/3061A61K 2039/507C07K 2317/34C07K 2317/56C07K 2317/90C07K 2317/94C07K 16/2803A61P 37/04A61P 37/02A61P 35/00A61P 31/00A61P 35/02C07K 2317/76C07K 2317/567C07K 2317/33C07K 2317/92C07K 2317/70C07K 2317/75C07K 2317/55A61K 2039/505A61P 37/00A61P 43/00Y02A50/30C07K 2317/24
84
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides anti-TIGIT (T-cell immunoreceptor with Ig and ITIM domains) antibodies and methods of using the same.

Claims

exact text as granted — not AI-modified
What is claimed is: 
     
         1 . An antibody that specifically binds to human TIGIT, wherein the antibody binds to an epitope on human TIGIT comprising one or more of amino acid residues Ser78, Ser80, and Lys82 of human TIGIT. 
     
     
         2 - 182 . (canceled)

Join the waitlist — get patent alerts

Track US2023279102A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.